MMJ International Holdings Pursuing Legal FDA Cannabis Medicine Approval

Last weeks announcement by Attorney General Sessions on the recision of the Cole Memorandum uniquely positions MMJ International Holdings as one of the only privately help companies pursuing the legal regulatory guidelines designated by the federal government for approval of a cannabis medicine.

MMJ International Holdings, the premier medical cannabis research company, is advancing the science of medical marijuana legally through patient clinical research and the operation of medical cannabis healthcare businesses, announced that its affiliate, MMJ Bioscience, has finalized a partnership agreement with Terra Life Science group, a private Canadian based pharmaceutical manufacturer, to produce cannabis medicines for the groups FDA approved studies.

https://www.justice.gov/opa/pr/justice-department-issues-memo-marijuana-enforcement

Last weeks announcement by Attorney General Sessions on the recision of the Cole Memorandum uniquely positions MMJ International Holdings as one of the only privately help companies pursuing the legal regulatory guidelines designated by the federal government for approval of a cannabis medicine.

Tim Moynahan, MMJ BioSciences chairman stated, ”The seasoned leadership team at MMJ BioSciences understands and executes its progressive development strategy in a legal, regulatory and fiscally responsible manner. Our company’s success is the result of our focus on identifying patient medical needs and addressing these patients needs by developing FDA approved medicines from the cannabis plant.”

Tim Moynahan further stated, ”We are excited to be a partner with Terra Life Sciences. This agreement enables MMJ BioScience with a significant product development capability. We anticipate a number of important synergies between the two companies that will be addressing patients needs with MMJ BioScience’s U.S. Food and Drug Administration (FDA) multiple sclerosis study beginning soon.”

Dr. Bianca Weinstock-Guttman, MMJ BioScience’s principal investigator is a Professor of Neurology at the State University of New York at Buffalo who serves as Executive Director of the New York State Multiple Sclerosis Consortium. Dr. Weinstock-Guttman will oversee the FDA approved study exploring the potential therapeutic applications of…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *